Chest 呼吸与危重症· Aparna C. Swaminathan, Susanna R. Stevens, Pooja Chopra, Peter Shrader, Eden Gebre, Scott M. Palmer, Lisa M. Wruck·· 2026-09-28AI 评分30
肺纤维化患者真实世界数据中抗纤维化药物剂量调整与临床结局关联
Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources
AI 导读
研究显示,肺纤维化患者中抗纤维化药物剂量减少和停药常见,主要因药物耐受性差。无论采用何种抗纤维化剂量策略,疾病进展在相当一部分患者中仍发生,强调了更有效且耐受性更好的肺纤维化治疗的迫切需求。
来源:Chest 呼吸与危重症 · journal.chestnet.org